Botanical Ingredient

Taxotere Safety Tips

Handling of Taxotere should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.

References

• 1. [Treatment of non-small cell lung cancer – where we are?]
  Milanowski J, Szmygin-Milanowska K.Pneumonol Alergol Pol. 2013;81(1):55-60. Polish.
• 2. [Effects of Docetaxel on Proliferation and Apoptosis of Human Multiple Myeloma Cell RPMI8226].
  Liu BL, Liu X, Qi MY, Zhou NC, Xu B.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Nov;20(6):1378-83. Chinese.
• 3. Inhibition of ZEB1 reverses the phenotype of epithelial-mesenchymal transition and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line SPC-A1/DTX.
  Ren J, Chen Y, Song H, Chen L, Wang R.J Cell Biochem. 2012 Dec 17. doi: 10.1002/jcb.24481. [Epub ahead of print]
• 4. Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes.
  Corcoran C, Rani S, O’Brien K, O’Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J, O’Driscoll L.PLoS One. 2012;7(12):e50999. doi: 10.1371/journal.pone.0050999. Epub 2012 Dec 10.
• 5. Update on taxane development: new analogs and new formulations.
  Yared JA, Tkaczuk KH.Drug Des Devel Ther. 2012;6:371-84. doi: 10.2147/DDDT.S28997. Epub 2012 Dec 11.
• 6. Low Expression of NQO1 Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Treated with TAC Regimen.
  Grim J, Jandík P, Slánská I, Dole?alová-Br?áková E, Fuksa L, Ryška A, Kní?ek J, Petera J, Mi?uda S, Hornychová H.Folia Biol (Praha). 2012;58(5):185-92.
• 7. Aberrant keap1 methylation in breast cancer and association with clinicopathological features.
  Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, la Torre A, Balsamo T, Poeta ML, Marangi GF, Maiello E, Castelvetere M, Pellegrini F, Murgo R, Fazio VM, Parrella P.Epigenetics. 2012 Dec 18;8(1). [Epub ahead of print]
• 8. A micro circulation system with a dialysis part for bioassays evaluating anticancer activity and retention.
  Imura Y, Yoshimura E, Sato K.Anal Chem. 2012 Dec 19. [Epub ahead of print]
• 9. Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1).
  Gonçalves A, Trédan O, Villanueva C, Dumontet C.Bull Cancer. 2012 Dec 14. [Epub ahead of print]
• 10. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
  Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; for the TRIO/BCIRG 001 investigators.Lancet Oncol. 2012 Dec 11. doi:pii: S1470-2045(12)70525-9.  10.1016/S1470-2045(12)70525-9. [Epub ahead of print]
• 11. Lethal pneumonitis after docetaxel chemotherapy: Case report and review of the literature.
  Storaas E, Holmaas G, Gravdal K, Børretzen A, Eikesdal HP.Acta Oncol. 2012 Dec 17. [Epub ahead of print] No abstract available.
• 12. Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis.
  Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y.Asian Pac J Cancer Prev. 2012;13(10):5177-82.
• 13. Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer.
  Roy C, Choudhury KB, Pal M, Saha A, Bag S, Banerjee C.Indian J Cancer. 2012 Jul;49(3):266-71. doi: 10.4103/0019-509X.104483.
• 14. [The treatment of castration-resistant prostate cancer].
  Petrányi A.Magy Onkol. 2012 Dec;56(4):219-28. doi: MagyOnkol.2012.56.4.219. Epub 2012 Oct 3. Hungarian.
• 15. Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate cancer.
  Rezvani H, Haghighi S, Ghadyani M, Attarian H.Urol J. 2012 Fall;9(4):673-7.
• 16. Evaluation of sources to document extended shelf lives of compounded cytostatics.
  Larsson I, Kart T.J Oncol Pharm Pract. 2012 Dec 12. [Epub ahead of print]
• 17. [Distal Gastrectomy for Initially Unresectable Gastric Cancer with Pyloric Stenosis Following Gastrojejunostomy and S-1 plus CDDP Chemotherapy].
  Sunahara M, Kawai T, Nagasako Y, Kobayashi S, Takahashi M, Ogasawara K, Kusano M, Kinoshita K, Miyagishima T.Gan To Kagaku Ryoho. 2012 Dec;39(13):2549-52. Japanese.
• 18. [A Case of HER2-Positive and AFP-Producing Gastric Cancer Successfully Treated by Trastuzumab/Docetaxel/S-1 Combination Therapy].
  Amano I, Sawai N, Mizuno C, Shaura Y, Nishiwaki M, Horimoto R, Oya H, Kato R, Seki K, Hashimoto H, Amakata Y, Matsumoto J, Tanaka I, Mizuno M, Shima T, Okanoue T.Gan To Kagaku Ryoho. 2012 Dec;39(13):2541-4. Japanese.
• 19. [Comparative examination of preparation time in docetaxel hydrate formulation].
  Arii D, Ikeno Y, Narita K, Murooka K, Nojima M, Kidokoro A.Gan To Kagaku Ryoho. 2012 Dec;39(13):2533-6. Japanese.
• 20. Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario.
  Caffo O, Veccia A, Russo L, Galligioni E.Future Oncol. 2012 Dec;8(12):1585-95. doi: 10.2217/fon.12.156.

Details